OBJECTIVE: To assess the effects of five-drug combination therapy on @entity2858 load in lymph nodes and subsequent maintenance with four and three drugs. METHODS: Ten pharmacotherapeutically naive @entity1 received a combination of @entity9611 , @entity16332 , @entity20706 , @entity486 , and @entity485 for 24 weeks, then @entity9611 , @entity16332 , @entity20706 , and @entity485 for the next 24 weeks, and finally @entity9611 , @entity16332 , and @entity485 for the last 24 weeks. @entity2858 RNA in lymph nodes was measured using quantitative polymerase chain reaction (PCR) at baseline, after 12, 24, 48, and 78 weeks. Plasma @entity2858 RNA, proviral DNA in peripheral blood mononuclear cells (PBMCs), circulating lymphocyte subsets, and protease inhibitor levels in blood were also regularly measured. Genotypic resistance was assessed in the different compartments in 2 @entity1 who were failed by therapy. RESULTS: @entity2858 RNA decreased in lymph nodes in 9 @entity1 and was stable in 1 despite initial control of plasma replication <20 copies/ml in each @entity1 . Lymph node levels rebounded in 1 @entity1 at week 72 as a result of lack of adherence and remained stable in the 8 others despite maintenance regimens. This represents a mean drop of -3.17 log in lymph nodes for the 8 @entity1 maintaining undetectable @entity646 at 72 weeks. In the @entity1 with stable lymph node viral RNA, selection of the @entity19899 mutation was demonstrated at this level before detection in plasma and low blood @entity485 levels were found throughout the study. Continuous improvements in immune parameters were observed in all cases, although PBMC proviral DNA levels either showed a continuous decrease or stabilized to a plateau. CONCLUSIONS: More complex regimens do not perform better in lymph nodes than classic triple therapy. The persistence of @entity2858 RNA in lymph nodes could be related with cellular resistance mechanisms rather than an insufficient potency of the regimens.

XXXX induction-maintenance at the lymph node level: the "Apollo-97" Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity9611 :: ('MESH:D015215', 'Chemical') :: ['zidovudine'] @entity16332 :: ('MESH:D019259', 'Chemical') :: ['lamivudine'] @entity646 :: ('MESH:D014766', 'Disease') :: ['viremia'] @entity2858 :: ('11676', 'Species') :: ['HIV-1'] @entity485 :: ('MESH:D019258', 'Chemical') :: ['saquinavir'] @entity20706 :: ('MESH:D016049', 'Chemical') :: ['didanosine'] @entity486 :: ('MESH:D019438', 'Chemical') :: ['ritonavir'] @entity19899 :: ('p|SUB|M|184|V', 'ProteinMutation') :: ['M184V']
@entity2858 :: (11676,Species) :: ['HIV-1']
